4.7 Article

Risk of Breast Cancer Among Carriers of Pathogenic Variants in Breast Cancer Predisposition Genes Varies by Polygenic Risk Score

期刊

JOURNAL OF CLINICAL ONCOLOGY
卷 39, 期 23, 页码 2564-+

出版社

LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1200/JCO.20.01992

关键词

-

类别

资金

  1. NIH [R01CA192393, R01CA225662, R35CA253187, U01CA164974, R01CA098663, R01CA100598, R01CA185623, P01CA151135, R01CA097396, P30CA16056, U01CA164973, U01CA164920, R01CA204819, R01CA77398, K24CA194251, K24CA194251-04S1]
  2. NIH Specialized Program of Research Excellence (SPORE) in Breast Cancer [P01CA116201]
  3. Breast Cancer Research Foundation
  4. NHLBI [HHSN268201600018C, HHSN268201600001C, HHSN268201600002C, HHSN268201600003C, HHSN268201600004C]
  5. NIEHS intramural awards [Z01-ES044005, Z01-ES049033, Z01-ES102245]
  6. American Cancer Society
  7. Karin Grunebaum Cancer Research Foundation
  8. University of Wisconsin-Madison Office of the Vice Chancellor for Research and Graduate Education
  9. California Breast Cancer
  10. California Department of Public Health
  11. California Breast Cancer Research Fund [97-10500]
  12. National Institutes of Health [R01 CA77398]
  13. California Department of Public Health, statewide cancer reporting program [103885]
  14. Morris and Horowitz Families Endowed Professorship
  15. the NIH [R01CA047147, R01CA067264, UM1CA186107, P01CA87969, R01CA49449, U01CA176726, R01CA67262, UL1TR002373, U01CA199277, P30CA014520, U01CA82004]

向作者/读者索取更多资源

This study evaluated the joint association of pathogenic variants in breast cancer predisposition genes and polygenic risk scores with breast cancer in the general population. The findings suggest that polygenic risk scores facilitate personalized breast cancer risk assessment among carriers of pathogenic variants in predisposition genes.
PURPOSE This study assessed the joint association of pathogenic variants (PVs) in breast cancer (BC) predisposition genes and polygenic risk scores (PRS) with BC in the general population. METHODS A total of 26,798 non-Hispanic white BC cases and 26,127 controls from predominately population-based studies in the Cancer Risk Estimates Related to Susceptibility consortium were evaluated for PVs in BRCA1, BRCA2, ATM, CHEK2, PALB2, BARD1, BRIP1, CDH1, and NF1. PRS based on 105 common variants were created using effect estimates from BC genome-wide association studies; the performance of an overall BC PRS and estrogen receptor-specific PRS were evaluated. The odds of BC based on the PVs and PRS were estimated using penalized logistic regression. The results were combined with age-specific incidence rates to estimate 5-year and lifetime absolute risks of BC across percentiles of PRS by PV status and first-degree family history of BC. RESULTS The estimated lifetime risks of BC among general-population noncarriers, based on 10th and 90th percentiles of PRS, were 9.1%-23.9% and 6.7%-18.2% for women with or without first-degree relatives with BC, respectively. Taking PRS into account, more than 95% of BRCA1, BRCA2, and PALB2 carriers had > 20% lifetime risks of BC, whereas, respectively, 52.5% and 69.7% of ATM and CHEK2 carriers without first-degree relatives with BC, and 78.8% and 89.9% of those with a first-degree relative with BC had > 20% risk. CONCLUSION PRS facilitates personalization of BC risk among carriers of PVs in predisposition genes. Incorporating PRS into BC risk estimation may help identify > 30% of CHEK2 and nearly half of ATM carriers below the 20% lifetime risk threshold, suggesting the addition of PRS may prevent overscreening and enable more personalized risk management approaches.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据